Breaking News, Trials & Filings

Teva, Active Biotech to Continue Nerventra Development

Despite CHMP opinion, companies will pursue multiple sclerosis indication

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Teva Pharmaceutical and Active Biotech will continue development of Nerventra (laquinimod) following the Committee for Medicinal Products for Human Use (CHMP) opinion to recommend against approval for the treatment of relapsing-remitting multiple sclerosis (RRMS) in the EU.   Both companies remain committed to the clinical development program for multiple sclerosis (MS) and will evaluate the CHMP feedback to determine potential next steps. To confirm the benefits of the drug on disability progre...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters